These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21633805)

  • 21. Neuregulin-1β induces proliferation, survival and paracrine signaling in normal human cardiac ventricular fibroblasts.
    Kirabo A; Ryzhov S; Gupte M; Sengsayadeth S; Gumina RJ; Sawyer DB; Galindo CL
    J Mol Cell Cardiol; 2017 Apr; 105():59-69. PubMed ID: 28263756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort.
    Geisberg CA; Abdallah WM; da Silva M; Silverstein C; Smith HM; Abramson V; Mayer I; Means-Powell J; Freehardt D; White B; Lenihan D; Sawyer DB
    J Card Fail; 2013 Jan; 19(1):10-5. PubMed ID: 23273589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
    de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
    Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure.
    De Keulenaer GW; Feyen E; Dugaucquier L; Shakeri H; Shchendrygina A; Belenkov YN; Brink M; Vermeulen Z; Segers VFM
    Circ Heart Fail; 2019 Oct; 12(10):e006288. PubMed ID: 31607147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.
    Schneider JW; Chang AY; Garratt A
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):22-8. PubMed ID: 12138394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuregulin as a heart failure therapy and mediator of reverse remodeling.
    Galindo CL; Ryzhov S; Sawyer DB
    Curr Heart Fail Rep; 2014 Mar; 11(1):40-9. PubMed ID: 24234399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
    Perez EA
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuregulin1 as novel therapy for heart failure.
    Yan X; Morgan JP
    Curr Pharm Des; 2011; 17(18):1808-17. PubMed ID: 21631420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
    Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
    Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERBB2 inhibition and heart failure.
    Cote GM; Sawyer DB; Chabner BA
    N Engl J Med; 2013 Feb; 368(9):876. PubMed ID: 23445109
    [No Abstract]   [Full Text] [Related]  

  • 32. ERBB2 inhibition and heart failure.
    Kühn B
    N Engl J Med; 2013 Feb; 368(9):875-6. PubMed ID: 23445110
    [No Abstract]   [Full Text] [Related]  

  • 33. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.
    Chien KR
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):9-14; discussion 92-100. PubMed ID: 11236034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity.
    Feldman AM; Lorell BH; Reis SE
    Circulation; 2000 Jul; 102(3):272-4. PubMed ID: 10899087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular effects of neuregulin-1/ErbB signaling: role in vascular signaling and angiogenesis.
    Hedhli N; Kalinowski A; S Russell K
    Curr Pharm Des; 2014; 20(30):4899-905. PubMed ID: 24283954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk.
    Lemmens K; Segers VF; Demolder M; De Keulenaer GW
    J Biol Chem; 2006 Jul; 281(28):19469-77. PubMed ID: 16698793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiotoxicity profile of trastuzumab.
    Ewer SM; Ewer MS
    Drug Saf; 2008; 31(6):459-67. PubMed ID: 18484781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. I-123-MIBG myocardial imaging in trastuzumab-based cardiotoxicity: the first experience.
    Stokkel MP; de Wit-van der Veen LJ; Boekhout A
    Nucl Med Commun; 2013 Jan; 34(1):19-24. PubMed ID: 23111379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzamab (Herceptin)-related cardiotoxicity in pregnancy.
    Roberts NJ; Auld BJ
    J R Soc Med; 2010 Apr; 103(4):157-9. PubMed ID: 20382907
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.